Silence Therapeutics PLC
NASDAQ:SLN
Intrinsic Value
Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SLN.
Silence Therapeutics PLC's market capitalization is 677.2m USD.
SLN stock price is 22.64 USD.
SLN.
SLN. Open DCF Valuation
SLN. Open Relative Valuation
SLN.
SLN's ROIC (Return on Invested Capital) has increased in the last 3 years from -74% to -72%, and is approaching profitability.
SLN's long-term assets (100m GBP) exceed its long-term liabilties (72m GBP).
SLN's ROE (Return on Equity) has significantly increased in the last 3 years from -92% to -82%, and is approaching profitability.
SLN has negative Operating Income for the last twelve months.
SLN has negative Net Income for the last twelve months.
SLN's ROE (Return on Equity) for the past 12 months is negative and is equal to -82%.
SLN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -72%.
SLN's Revenue is forecast to grow at a rate of 408% per year over the next 3 years.
SLN has positive Free Cash Flow for the last twelve months.
SLN has negative three-year average ROE (Return on Equity): -76%. The company is not efficient at transforming stockholders' equity into net income.
SLN has negative three-year average ROIC (Return on Invested Capital): -114%. The company is not efficient at using invested capital to generate operating income.
SLN's short-term assets (91m GBP) exceed its short-term liabilties (9m GBP).
SLN's D/E (Debt to Equity) is very low and is equal to 0.
SLN's Altman Z-Score is very low and is equal to -0.21.
Fundamental Analysis
Silence Therapeutics PLC
Balance Sheet Decomposition
Silence Therapeutics PLC
| Current Assets | 90.7m |
| Cash & Short-Term Investments | 50.3m |
| Receivables | 38.3m |
| Other Current Assets | 2.1m |
| Non-Current Assets | 9.4m |
| Long-Term Investments | 293k |
| PP&E | 832k |
| Intangibles | 28k |
| Other Non-Current Assets | 8.2m |
| Current Liabilities | 9.2m |
| Other Current Liabilities | 9.2m |
| Non-Current Liabilities | 63.2m |
| Other Non-Current Liabilities | 63.2m |
Earnings Waterfall
Silence Therapeutics PLC
|
Revenue
|
1.4m
GBP
|
|
Operating Expenses
|
-28.6m
GBP
|
|
Operating Income
|
-27.2m
GBP
|
|
Other Expenses
|
4.8m
GBP
|
|
Net Income
|
-22.4m
GBP
|
Free Cash Flow Analysis
Silence Therapeutics PLC
What is Free Cash Flow?
SLN Profitability Score
Profitability Due Diligence
Silence Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Silence Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
SLN Solvency Score
Solvency Due Diligence
Silence Therapeutics PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Silence Therapeutics PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SLN Price Targets Summary
Silence Therapeutics PLC
Shareholder Return
SLN Price
Silence Therapeutics PLC
| Average Annual Return | -5.3% |
| Standard Deviation of Annual Returns | 31.08% |
| Max Drawdown | -84% |
| Market Capitalization | 677.2m USD |
| Shares Outstanding | 29 913 300 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Silence Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. The firm is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a), or Lp(a), levels and SLN124, for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome (MDS).
You don't have any saved screeners yet
